Advertisement

Treatment of Localized Prostate Cancer

  • Andrew J. StephensonEmail author
Chapter
Part of the Current Clinical Urology book series (CCU)

Abstract

In the USA, mass opportunistic screening has resulted in the increased detection of prostate cancer and an increased proportion of patients who are candidates for curative therapy. Screening has also resulted in the increased detection of low-risk cancers that may pose a relatively low threat to survival and quality of life, particularly for patients with limited life expectancy. No treatment has been definitively proven to be superior to another in terms of quantity and quality of life. However, all definitive treatments (radical prostatectomy, EBRT, and brachytherapy) may negatively impact urinary, bowel, and sexual function. As there are substantial trade-offs between in terms of benefits and risks of treatments that are likely sensitive to patient preferences, it is recommended that patients be informed of all potential treatments options with adherence to published guidelines. In general, there is an underutilization of active surveillance, particularly for low-risk patients and those with limited life expectancy. Radical prostatectomy and external-beam radiotherapy with 2–3 years of adjuvant androgen deprivation therapy are the standard options for high-risk disease. The outcomes of patients undergoing definitive local therapy are favorable, particularly in terms of the low risk of clinical disease progression and serious morbidity. Outcomes appear to be sensitive to the expertise and skill of the treating urologist and oncologist.

Keywords

Prostate Cancer Radical Prostatectomy Androgen Deprivation Therapy Active Surveillance Localize Prostate Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.PubMedGoogle Scholar
  2. 2.
    Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer. 2004;100(7):1397–405.PubMedGoogle Scholar
  3. 3.
    Makinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, et al. Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen. Clin Cancer Res. 2003;9(7):2435–9.PubMedGoogle Scholar
  4. 4.
    van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van der Kwast TH, et al. Comparison of screen detected and clinically diagnosed prostate cancer in the European randomized study of screening for prostate cancer, section rotterdam. J Urol. 2005;174(1):121–5.PubMedGoogle Scholar
  5. 5.
    Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol. 2008;9(5):445–52.PubMedGoogle Scholar
  6. 6.
    Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008;19(2):175–81.PubMedGoogle Scholar
  7. 7.
    Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst. 2003;95(12):868–78.PubMedGoogle Scholar
  8. 8.
    Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360(13):1320–8.PubMedGoogle Scholar
  9. 9.
    Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst. 2009;101(19):1325–9.PubMedGoogle Scholar
  10. 10.
    Walter LC, Bertenthal D, Lindquist K, Konety BR. PSA screening among elderly men with limited life expectancies. Jama. 2006;296(19):2336–42.PubMedGoogle Scholar
  11. 11.
    Barocas DA, Cowan JE, Smith JA, Jr., Carroll PR. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol. 2008;180(4):1330–4; discussion 4–5.PubMedGoogle Scholar
  12. 12.
    Harlan SR, Cooperberg MR, Elkin EP, Lubeck DP, Meng MV, Mehta SS, et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol. 2003;170(5):1804–7.PubMedGoogle Scholar
  13. 13.
    Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. Jama. 2005;293(17):2095–101.PubMedGoogle Scholar
  14. 14.
    Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94(13):981–90.PubMedGoogle Scholar
  15. 15.
    Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, et al. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst. 2009;101(6):374–83.PubMedGoogle Scholar
  16. 16.
    Parker C, Muston D, Melia J, Moss S, Dearnaley D. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer. 2006;94(10):1361–8.PubMedGoogle Scholar
  17. 17.
    Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18):1708–17.PubMedGoogle Scholar
  18. 18.
    Bianco FJ, Jr., Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (“trifecta”). Urology. 2005;66(5 Suppl):83–94.PubMedGoogle Scholar
  19. 19.
    Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. Jama. 2005;294(4):433–9.PubMedGoogle Scholar
  20. 20.
    Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. Jama. 1999;281(17):1591–7.PubMedGoogle Scholar
  21. 21.
    D’Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351(2):125–35.PubMedGoogle Scholar
  22. 22.
    Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst. 2011;103(6):462–9.PubMedGoogle Scholar
  23. 23.
    O’Brien MF, Cronin AM, Fearn PA, Smith B, Stasi J, Guillonneau B, et al. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. J Clin Oncol. 2009;27(22):3591–7.PubMedGoogle Scholar
  24. 24.
    Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, et al. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst. 2008;100:1144–54.PubMedGoogle Scholar
  25. 25.
    Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301–8.PubMedGoogle Scholar
  26. 26.
    Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, et al. The Prostate cancer intervention versus observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials. 2009;30:81–7.PubMedGoogle Scholar
  27. 27.
    D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–74.PubMedGoogle Scholar
  28. 28.
    Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173:1938–42.PubMedGoogle Scholar
  29. 29.
    Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–71.PubMedGoogle Scholar
  30. 30.
    Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011;185:869–75.PubMedGoogle Scholar
  31. 31.
    Kattan MW, Cuzick J, Fisher G, Berney DM, Oliver T, Foster CS, et al. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer. 2007;112:69–74.Google Scholar
  32. 32.
    Kattan MW, Cuzick J, Fisher G, Berney DM, Oliver T, Foster CS, et al. A nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer. 2008;112:69–74.PubMedGoogle Scholar
  33. 33.
    Kattan MW, Wheeler TM, Scardino PT. Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol. 1999;17:1499–507.PubMedGoogle Scholar
  34. 34.
    Potters L, Roach M, 3rd, Davis BJ, Stock RG, Ciezki JP, Zelefsky MJ, et al. Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable. Int J Radiat Oncol Biol Phys. 2010;76:1061–5.PubMedGoogle Scholar
  35. 35.
    Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ, Jr., Yossepowitch O, Vickers AJ, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009;27:4300–5.PubMedGoogle Scholar
  36. 36.
    Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Jr., Dotan ZA, Diblasio CJ, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23:7005–12.PubMedGoogle Scholar
  37. 37.
    Stephenson AJ, Scardino PT, Eastham JA, Bianco FJ, Jr., Dotan ZA, Fearn PA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98:715–7.PubMedGoogle Scholar
  38. 38.
    Zelefsky MJ, Kattan MW, Fearn P, Fearon BL, Stasi JP, Shippy AM, et al. Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. Urology. 2007;70:283–7.PubMedGoogle Scholar
  39. 39.
    Meehl PE. Causes and effects of my disturbing little book. J Pers Assess. 1986;50:370–5.PubMedGoogle Scholar
  40. 40.
    Kattan MW. Expert Systems in Medicine. In: Smelser NJ, Baltes PB, editors. International encyclopedia of the social & behavioral sciences. Oxford: Pergamon; 2001. p. 5135–9.Google Scholar
  41. 41.
    Ross PL, Gerigk C, Gonen M, Yossepowitch O, Cagiannos I, Sogani PC, et al. Comparisons of nomograms and urologists’ predictions in prostate cancer. Semin Urol Oncol. 2002;20:82–8.PubMedGoogle Scholar
  42. 42.
    D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol. 1995;154:131–8.PubMedGoogle Scholar
  43. 43.
    Kattan MW, Leung DH, Brennan MF. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol. 2002;20:791–6.PubMedGoogle Scholar
  44. 44.
    Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000;18:3352–9.PubMedGoogle Scholar
  45. 45.
    Kattan MW, Zelefsky MJ, Kupelian PA, Cho D, Scardino PT, Fuks Z, et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J Clin Oncol. 2003;21:4568–71.PubMedGoogle Scholar
  46. 46.
    Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166:63–7.PubMedGoogle Scholar
  47. 47.
    Mitchell JA, Cooperberg MR, Elkin EP, Lubeck DP, Mehta SS, Kane CJ, et al. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE. J Urol. 2005;173:1126–31.PubMedGoogle Scholar
  48. 48.
    Kawachi MH, Bahnson RR, Barry M, Busby JE, Carroll PR, Carter HB, et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw. 2010;8:162–200.PubMedGoogle Scholar
  49. 49.
    Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68–80.PubMedGoogle Scholar
  50. 50.
    Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–31.PubMedGoogle Scholar
  51. 51.
    Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol. 2005;23:8146–51.PubMedGoogle Scholar
  52. 52.
    Vickers AJ, Bianco FJ, Jr., Boorjian S, Scardino PT, Eastham JA. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer. 2011;117:2883–91.PubMedGoogle Scholar
  53. 53.
    Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010;116:5226–34.PubMedGoogle Scholar
  54. 54.
    Kibel AS, Ciezki JP, Klein EA, Reddy CA, Lubahn JD, Haslag-Minoff J, et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol 2012;187(4):1259–65.Google Scholar
  55. 55.
    Zelefsky MJ, Eastham JA, Cronin AM, Fuks Z, Zhang Z, Yamada Y, et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol. 2010;28:1508–13.PubMedGoogle Scholar
  56. 56.
    Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358:1250–61.PubMedGoogle Scholar
  57. 57.
    Litwin MS, Gore JL, Kwan L, Brandeis JM, Lee SP, Withers HR, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for early-stage prostate cancer. Cancer. 2007;109:2239–47.PubMedGoogle Scholar
  58. 58.
    Pardo Y, Guedea F, Aguilo F, Fernandez P, Macias V, Marino A, et al. Quality-of-life impact of primary treatments for localized prostate cancer in patients without hormonal treatment. J Clin Oncol. 2010;28:4687–96.PubMedGoogle Scholar
  59. 59.
    Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96:1358–67.PubMedGoogle Scholar
  60. 60.
    Johansson E, Steineck G, Holmberg L, Johansson JE, Nyberg T, Ruutu M, et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol. 2011;12:891–9.PubMedGoogle Scholar
  61. 61.
    Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol. 2010;28:126–31.PubMedGoogle Scholar
  62. 62.
    Carter HB, Kettermann A, Warlick C, Metter EJ, Landis P, Walsh PC, et al. Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. J Urol. 2007;178:2359–64. discussion 2364–5.PubMedGoogle Scholar
  63. 63.
    Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst. 2006;98:355–7.PubMedGoogle Scholar
  64. 64.
    Patel MI, De CD, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT. An analysis of men with clinically localized prostate cancer who deferred definitive therapy. J Urol. 2004;171:1520–4.PubMedGoogle Scholar
  65. 65.
    Eggener SE, Mueller A, Berglund RK, Ayyathurai R, Soloway C, Soloway MS, et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol. 2009;181:1635–41. discussion 1641.PubMedGoogle Scholar
  66. 66.
    Carter CA, Donahue T, Sun L, Wu H, McLeod DG, Amling C, et al. Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. J Clin Oncol. 2003;21:4001–8.PubMedGoogle Scholar
  67. 67.
    van den Bergh RC, Vasarainen H, van der Poel HG, Vis-Maters JJ, Rietbergen JB, Pickles T, et al. Short-term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study. BJU Int. 2010;105(7):956–62.PubMedGoogle Scholar
  68. 68.
    van As NJ, Norman AR, Thomas K, Khoo VS, Thompson A, Huddart RA, et al. Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance. Eur Urol. 2008;54:1297–305.PubMedGoogle Scholar
  69. 69.
    Miocinovic R, Jones JS, Pujara AC, Klein EA, Stephenson AJ. Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria. Urology. 2011;77:980–4.PubMedGoogle Scholar
  70. 70.
    Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2011;11:725–32.Google Scholar
  71. 71.
    Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience. BJU Int. 2008;101:165–9.PubMedGoogle Scholar
  72. 72.
    van den Bergh RC, Steyerberg EW, Khatami A, Aus G, Pihl CG, Wolters T, et al. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer. 2010;116:1281–90.PubMedGoogle Scholar
  73. 73.
    Duffield AS, Lee TK, Miyamoto H, Carter HB, Epstein JI. Radical prostatectomy findings in patients in whom active surveillance of prostate cancer fails. J Urol. 2009;182:2274–8.PubMedGoogle Scholar
  74. 74.
    Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol. 2008;180:1964–7. discussion 1967–8.PubMedGoogle Scholar
  75. 75.
    Saranchuk JW, Kattan MW, Elkin E, Touijer AK, Scardino PT, Eastham JA. Achieving optimal outcomes after radical prostatectomy. J Clin Oncol. 2005;23:4146–51.PubMedGoogle Scholar
  76. 76.
    Farnham SB, Webster TM, Herrell SD, Smith Jr JA. Intraoperative blood loss and transfusion requirements for robotic-assisted radical prostatectomy versus radical retropubic prostatectomy. Urology. 2006;67:360–3.PubMedGoogle Scholar
  77. 77.
    Webster TM, Herrell SD, Chang SS, Cookson MS, Baumgartner RG, Anderson LW, et al. Robotic assisted laparoscopic radical prostatectomy versus retropubic radical prostatectomy: a prospective assessment of postoperative pain. J Urol. 2005;174:912–4. discussion 914.PubMedGoogle Scholar
  78. 78.
    Nelson B, Kaufman M, Broughton G, Cookson MS, Chang SS, Herrell SD, et al. Comparison of length of hospital stay between radical retropubic prostatectomy and robotic assisted laparoscopic prostatectomy. J Urol. 2007;177:929–31.PubMedGoogle Scholar
  79. 79.
    Wood DP, Schulte R, Dunn RL, Hollenbeck BK, Saur R, Wolf JS, Jr., et al. Short-term health outcome differences between robotic and conventional radical prostatectomy. Urology. 2007;70:945–9.PubMedGoogle Scholar
  80. 80.
    Smith JA, Jr., Chan RC, Chang SS, Herrell SD, Clark PE, Baumgartner R, et al. A comparison of the incidence and location of positive surgical margins in robotic assisted laparoscopic radical prostatectomy and open retropubic radical prostatectomy. J Urol. 2007;178:2385–9. discussion 2389–90.PubMedGoogle Scholar
  81. 81.
    Touijer K, Kuroiwa K, Eastham JA, Vickers A, Reuter VE, Scardino PT, et al. Risk-adjusted analysis of positive surgical margins following laparoscopic and retropubic radical prostatectomy. Eur Urol. 2007;52:1090–6.PubMedGoogle Scholar
  82. 82.
    Touijer K, Eastham JA, Secin FP, Romero Otero J, Serio A, Stasi J, et al. Comprehensive prospective comparative analysis of outcomes between open and laparoscopic radical prostatectomy conducted in 2003 to 2005. J Urol. 2008;179:1811–7. discussion 1817.PubMedGoogle Scholar
  83. 83.
    Vickers AJ, Bianco FJ, Serio AM, Eastham JA, Schrag D, Klein EA, et al. The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst. 2007;99:1171–7.PubMedGoogle Scholar
  84. 84.
    Vickers AJ, Savage CJ, Hruza M, Tuerk I, Koenig P, Martinez-Pineiro L, et al. The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study. Lancet Oncol. 2009;10:475–80.PubMedGoogle Scholar
  85. 85.
    Eastham JA, Kattan MW, Riedel E, Begg CB, Wheeler TM, Gerigk C, et al. Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol. 2003;170:2292–5.PubMedGoogle Scholar
  86. 86.
    Begg CB, Riedel ER, Bach PB, Kattan MW, Schrag D, Warren JL, et al. Variations in morbidity after radical prostatectomy. N Engl J Med. 2002;346:1138–44.PubMedGoogle Scholar
  87. 87.
    Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;191:956–62.Google Scholar
  88. 88.
    Stephenson AJ, Shariat SF, Zelefsky MJ, Kattan MW, Butler EB, Teh BS, et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA. 2004;291:1325–32.PubMedGoogle Scholar
  89. 89.
    Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet. 2005;366:572–8.PubMedGoogle Scholar
  90. 90.
    Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol. 2003;170:791–4.PubMedGoogle Scholar
  91. 91.
    Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy  >  or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:25–33.PubMedGoogle Scholar
  92. 92.
    Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003;57:915–28.PubMedGoogle Scholar
  93. 93.
    Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500.PubMedGoogle Scholar
  94. 94.
    Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Jr., Miller DW, Adams JA, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294:1233–9.PubMedGoogle Scholar
  95. 95.
    Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002;360:103–6.PubMedGoogle Scholar
  96. 96.
    Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02. J Clin Oncol. 2003;21:3972–8.PubMedGoogle Scholar
  97. 97.
    D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289–95.PubMedGoogle Scholar
  98. 98.
    Lawton CA, DeSilvio M, Roach M, 3rd, Uhl V, Kirsch R, Seider M, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94–13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. 2007;69:646–55.PubMedGoogle Scholar
  99. 99.
    Bianco FJ, Jr., Scardino PT, Stephenson AJ, Diblasio CJ, Fearn PA, Eastham JA. Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:448–53.PubMedGoogle Scholar
  100. 100.
    Izawa JI, Madsen LT, Scott SM, Tran JP, McGuire EJ, Von Eschenbach AC, et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol. 2002;20:2664–71.PubMedGoogle Scholar
  101. 101.
    Pisters LL, Rewcastle JC, Donnelly BJ, Lugnani FM, Katz AE, Jones JS. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol. 2008;180:559–63. discussion 563–4.PubMedGoogle Scholar
  102. 102.
    Stephenson AJ, Scardino PT, Bianco FJ, Jr., Diblasio CJ, Fearn PA, Eastham JA. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol. 2004;172:2239–43.PubMedGoogle Scholar
  103. 103.
    Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer. 2000;88:398–406.PubMedGoogle Scholar
  104. 104.
    Moon K, Stukenborg GJ, Keim J, Theodorescu D. Cancer incidence after localized therapy for prostate cancer. Cancer. 2006;107:991–8.PubMedGoogle Scholar
  105. 105.
    D’Amico AV, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, et al. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J Clin Oncol. 2009;27(24):3923–8.PubMedGoogle Scholar
  106. 106.
    Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 1997;79:235–46.Google Scholar
  107. 107.
    Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not ­suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006;24:1868–76.PubMedGoogle Scholar
  108. 108.
    Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol. 2005;23:7897–903.PubMedGoogle Scholar
  109. 109.
    Krupski TL, Smith MR, Chan Lee W, Pashos CL, Brandman J, Wang Q, et al. Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy. Cancer. 2004;101:541–9.PubMedGoogle Scholar
  110. 110.
    D’Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420–5.PubMedGoogle Scholar
  111. 111.
    Nanda A, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009;302:866–73.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Glickman Urologic and Kidney Institute, Cleveland ClinicClevelandUSA

Personalised recommendations